amarincorp.com (AMRN): שווי פעילות לרווח לפני ריבית, מסים ופחת

Revenue declines due to pressure from competitors in the US are already priced in, yet threats of capital shortages and the loss of exclusive drug rights persist. This EV/EBITDA chart on GURU.Markets shows the current metric at 0.00. Amarin Corporation plc (AMRN), the developer of the cardiovascular drug Vascepa, is relying on seeking partners, new trials, and expansion into European countries to stimulate share price growth.

Investors are evaluating Amarin Corporation plc (AMRN) through the lens of high dependency on a single drug amidst patent wars. The EV/EBITDA multiple compares enterprise value, including debt, with operating profit before taxes to reveal the asset's real value. Analyzing the EV/EBITDA trend of the business highlights how the risk of generic expansion impacts market expectations, allowing for the identification of the tipping point between fundamental undervaluation and unjustified optimism.